SLU-PP-332

Overview

SLU-PP-332 is not a peptide but a small synthetic molecule, and is included here because it is frequently grouped with research compounds in the metabolic category. It is an agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), a family of orphan nuclear receptors involved in mitochondrial biogenesis and oxidative metabolism. Published work describes it as an 'exercise mimetic': a compound that induces transcriptional programmes resembling those triggered by aerobic exercise. The published record is entirely preclinical — cell and rodent work — and the compound has also attracted attention from anti-doping researchers, who have published analytical methods for detecting it.

For research use only · Not FDA/EMA approved · Not for human consumption

Mechanism of Action

Published research describes SLU-PP-332 as a pan-agonist across the ERR isoforms, with activity reported at ERRα, ERRβ and ERRγ. ERR activation is described in the literature as driving transcriptional programmes governing mitochondrial biogenesis, fatty acid oxidation and oxidative phosphorylation. A 2023 study in ACS Chemical Biology reported that the compound induced an ERRα-dependent acute aerobic exercise response and enhanced exercise capacity in mice, with the ERRα dependence established using receptor-deficient animals. Subsequent published work examined effects on parameters of metabolic syndrome in rodent models.

For research use only · Not FDA/EMA approved · Not for human consumption

Key Research Areas

• ERRα-dependent induction of an acute aerobic exercise transcriptional response
• Exercise capacity in rodent models
• Metabolic syndrome parameters in preclinical studies
• Mitochondrial biogenesis and fatty acid oxidation
• Analytical detection methods for anti-doping purposes

For research use only · Not FDA/EMA approved · Not for human consumption

Published Studies (4 cited)

For research use only · Not FDA/EMA approved · Not for human consumption

Dosage in Published Research

Published preclinical studies administered SLU-PP-332 to rodents by intraperitoneal injection, with doses in published protocols reported in the low mg/kg range and typically given daily over multi-week study periods. Cell-based work reports activity at micromolar concentrations. No human dosing data exists. All figures are reported from published preclinical literature for reference purposes only.

For research use only · Not FDA/EMA approved · Not for human consumption

Storage & Handling

Store the solid at -20°C, protected from light and moisture. As a small molecule rather than a peptide, it is typically prepared in an organic solvent such as DMSO for stock solutions in published protocols; aqueous solubility is limited. Store stock solutions at -20°C and avoid repeated freeze-thaw cycles. Handle under laboratory conditions using appropriate PPE.

For research use only · Not FDA/EMA approved · Not for human consumption

Safety Profile (Literature Only)

No human clinical data exists for SLU-PP-332 and no LD50 has been established. The published record consists of preclinical rodent and cell studies, which report tolerability within the specific protocols examined but do not constitute a safety characterisation. Published anti-doping literature indicates that the compound is treated as a substance of concern in sport. This compound is supplied for laboratory research use only.

For research use only · Not FDA/EMA approved · Not for human consumption